Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4.
Effects of Tysabri over 12 months on multiple sclerosis (MS) related fatigue in patients with relapsing remitting multiple sclerosis (RRMS) (TYNERGY)
Fatigue and heat sensitivity in patients with multiple sclerosis.
Structural correlates for fatigue in early relapsing remitting multiple sclerosis.
Successful antiviral treatment of chronic hepatitis C in patients with rare comorbidities. Two case-reports.
New pharmacological approaches against chronic bowel and bladder problems in paralytics.
Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients.
Autopsy-proven demyelination associated with infliximab treatment.
Anti-annexin antibodies, cholesterol levels and disability in multiple sclerosis.
No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy.
The experiences of support persons of people newly diagnosed with multiple sclerosis: an interpretative phenomenological study.
[Chronic inflammatory demyelinating polyradiculoneuropathy(CIDP): Treatment and prognosis].
[Symptoms and neurological findings in patients with multiple sclerosis].
Chemotactic signaling and beyond: link between interleukin-16 and axonal degeneration in multiple sclerosis.
A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study.
Identification of genetic determinants of the sexual dimorphism in CNS autoimmunity.
[Do new oral therapies show advantages in the basal therapy of multiple sclerosis? Con.]
YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.
Acute Respiratory Failure due to Neuromyelitis Optica Treated Successfully with Plasmapheresis.
Regulator of G-protein Signaling (RGS)1 and RGS10 Proteins as Potential Drug Targets for Neuroinflammatory and Neurodegenerative Diseases.
Albumin and multiple sclerosis.
Conformational Changes and Association of Membrane-Interacting Peptides in Myelin Membrane Models: A Case of the C-Terminal Peptide of Proteolipid Protein and the Antimicrobial Peptide Melittin.
Misfiring in multiple sclerosis: Cerebellar Channelopathy, a Potential Novel Target?
Control of microglial neurotoxicity by the fractalkine receptor.
Alterations in hippocampal myelin and oligodendrocyte precursor cells during epileptogenesis.
Pages
« first
‹ previous
…
674
675
676
677
678
679
680
681
682
…
next ›
last »